Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Achieve Life Sciences (ACHV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and Achieve Life Sciences (ACHV – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Abbott Laboratories (ABT)

UBS analyst Danielle Antalffy maintained a Buy rating on Abbott Laboratories today and set a price target of $158.00. The company’s shares closed last Thursday at $127.63.

According to TipRanks.com, Antalffy is a 3-star analyst with an average return of 2.5% and a 51.6% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Treace Medical Concepts, and Zimmer Biomet Holdings. ;'>

Currently, the analyst consensus on Abbott Laboratories is a Strong Buy with an average price target of $146.65, which is a 13.2% upside from current levels. In a report issued on October 10, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $145.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Achieve Life Sciences (ACHV)

JonesTrading analyst Justin Walsh reiterated a Buy rating on Achieve Life Sciences today and set a price target of $20.00. The company’s shares closed last Thursday at $3.08.

According to TipRanks.com, Walsh is a 4-star analyst with an average return of 7.1% and a 37.9% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Praxis Precision Medicines. ;'>

Achieve Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $13.25, implying a 311.5% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.

Read More on ABT:

Disclaimer & DisclosureReport an Issue

• Abbott price target raised to $162 from $159 at Barclays
• Abbott price target lowered to $142 from $144 at Evercore ISI
• Abbott price target raised to $146 from $141 at Raymond James
• Abbott price target raised to $146 from $142 at Wells Fargo
• Abbott Laboratories: Strong Growth Prospects and Stable Financial Health Drive Buy Rating